Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Антиангиогенная терапия при раке молочной железы с тройным негативным фенотипом
Антиангиогенная терапия при раке молочной железы с тройным негативным фенотипом
Ганьшина И.П., Иванова К.А., Гордеева О.О., Архипов А.В., Жукова Л.Г. Антиангиогенная терапия при раке молочной железы с тройным негативным фенотипом. Современная Онкология. 2021; 23 (1): 88–92.
DOI: 10.26442/18151434.2021.1.200763
DOI: 10.26442/18151434.2021.1.200763
DOI: 10.26442/18151434.2021.1.200763
________________________________________________
DOI: 10.26442/18151434.2021.1.200763
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Трижды негативный рак молочной железы (ТНРМЖ) составляет 10–24% всех случаев рака молочной железы (РМЖ), характеризуется отсутствием в опухоли рецепторов к эстрогенам, прогестерону и HER-2. Терапия данного заболевания является трудной клинической задачей. В отличие от гормонопозитивного и HER-2-позитивного РМЖ, при которых мы успешно применяем таргетные препараты (антиэстрогены и анти-HER-2-препараты), при ТНРМЖ мы долгое время не имели таких мишеней. Так, несмотря на впечатляющие результаты иммунотерапии метастатического ТНРМЖ, остается достаточно большая группа пациенток с отрицательным PD-L1-статусом, для которых необходимо разрабатывать иные стратегии лечения. Один из подходов в лечении злокачественных опухолей предусматривает воздействие не на опухолевые клетки, а на процесс новообразования сосудов в опухоли – ангиогенез. Антиангиогенные препараты положительно зарекомендовали себя при лечении большого количества злокачественных опухолей, но являются недооцененными для РМЖ (в том числе для тройного негативного фенотипа). Применение бевацизумаба в комбинации с цитостатиками на различных этапах лечения пациенток с РМЖ изучалось в многочисленных клинических исследованиях и продемонстрировало обнадеживающие результаты, в том числе и для ТНРМЖ, однако из-за отозванной регистрации Управлением по контролю пищевых продуктов и лекарств в США было незаслуженно забыто в ряде стран. В данном обзоре представлена роль бевацизумаба в терапии пациенток с ТНРМЖ и предложены условия, при которых назначение этого препарата было бы оправданным и приводило к лучшим результатам.
Ключевые слова: трижды негативный рак молочной железы, ангиогенез, бевацизумаб, антиангиогенная терапия
Keywords: triple-negative breast cancer, angiogenesis, bevacizumab, antiangiogenic therapy
Ключевые слова: трижды негативный рак молочной железы, ангиогенез, бевацизумаб, антиангиогенная терапия
________________________________________________
Keywords: triple-negative breast cancer, angiogenesis, bevacizumab, antiangiogenic therapy
Полный текст
Список литературы
1. Folkman J. Tumor Angiogenesis: Therapeutic Implications. N Engl J Med 1971; 285 (21): 1182–6. DOI: 10.1056/nejm197111182852108
2. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7 (9): 987–9.
3. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58–62.
4. Duda DG, Jain RK, Willett CG. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25 (26): 4033–42.
5. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27 (30): 4966–72.
6. Miles DW, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26 (43s).
7. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29 (10): 1252–60.
8. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010; 28 (Suppl. 15): 1005.
9. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients Ann Oncol [epub ahead of print on September 5, 2010].
10. Smith I, Pierga JY, Biganzoli L, et al. Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 2011; 130: 133.
11. Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer. Lancet Oncol 2014; 15 (12): 1351–60.
12. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. J Clin Oncol 2011; 29 (32): 4286–93. DOI: 10.1200/jco.2010.34.1255
13. O’Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: Phase III Trials of Bevacizumab with Standard Chemotherapy for Metastatic Breast Cancer. Clin Breast Cancer 2008. 8(4); 370–3. DOI: 10.3816/cbc.2008.n.045
14. Nahleh Z, Botrus G, Dwivedi A, et al. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol 2019; 10: 357–65.
15. Hardy-Bessard AC, Brocard F, Clatot F, et al. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast 2020; 54: 256–63. DOI: 10.1016/j.breast.2020.09.011
16. De Angelis C, Bruzzese D, Bernardo A, et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open 2021; 6 (2): 100054. DOI: 10.1016/j.esmoop.2021.100054. PMID: 33601296.
17. Hirai T, Nemoto A, Ito Y, et al. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer. Breast Cancer Res Treat 2020; 181: 189–98. DOI: 10.1007/s10549-020-05615-4
2. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7 (9): 987–9.
3. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58–62.
4. Duda DG, Jain RK, Willett CG. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25 (26): 4033–42.
5. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27 (30): 4966–72.
6. Miles DW, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26 (43s).
7. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29 (10): 1252–60.
8. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010; 28 (Suppl. 15): 1005.
9. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients Ann Oncol [epub ahead of print on September 5, 2010].
10. Smith I, Pierga JY, Biganzoli L, et al. Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 2011; 130: 133.
11. Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer. Lancet Oncol 2014; 15 (12): 1351–60.
12. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. J Clin Oncol 2011; 29 (32): 4286–93. DOI: 10.1200/jco.2010.34.1255
13. O’Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: Phase III Trials of Bevacizumab with Standard Chemotherapy for Metastatic Breast Cancer. Clin Breast Cancer 2008. 8(4); 370–3. DOI: 10.3816/cbc.2008.n.045
14. Nahleh Z, Botrus G, Dwivedi A, et al. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol 2019; 10: 357–65.
15. Hardy-Bessard AC, Brocard F, Clatot F, et al. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast 2020; 54: 256–63. DOI: 10.1016/j.breast.2020.09.011
16. De Angelis C, Bruzzese D, Bernardo A, et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open 2021; 6 (2): 100054. DOI: 10.1016/j.esmoop.2021.100054. PMID: 33601296.
17. Hirai T, Nemoto A, Ito Y, et al. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer. Breast Cancer Res Treat 2020; 181: 189–98. DOI: 10.1007/s10549-020-05615-4
2. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7 (9): 987–9.
3. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58–62.
4. Duda DG, Jain RK, Willett CG. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25 (26): 4033–42.
5. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27 (30): 4966–72.
6. Miles DW, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26 (43s).
7. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29 (10): 1252–60.
8. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010; 28 (Suppl. 15): 1005.
9. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients Ann Oncol [epub ahead of print on September 5, 2010].
10. Smith I, Pierga JY, Biganzoli L, et al. Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 2011; 130: 133.
11. Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer. Lancet Oncol 2014; 15 (12): 1351–60.
12. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. J Clin Oncol 2011; 29 (32): 4286–93. DOI: 10.1200/jco.2010.34.1255
13. O’Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: Phase III Trials of Bevacizumab with Standard Chemotherapy for Metastatic Breast Cancer. Clin Breast Cancer 2008. 8(4); 370–3. DOI: 10.3816/cbc.2008.n.045
14. Nahleh Z, Botrus G, Dwivedi A, et al. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol 2019; 10: 357–65.
15. Hardy-Bessard AC, Brocard F, Clatot F, et al. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast 2020; 54: 256–63. DOI: 10.1016/j.breast.2020.09.011
16. De Angelis C, Bruzzese D, Bernardo A, et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open 2021; 6 (2): 100054. DOI: 10.1016/j.esmoop.2021.100054. PMID: 33601296.
17. Hirai T, Nemoto A, Ito Y, et al. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer. Breast Cancer Res Treat 2020; 181: 189–98. DOI: 10.1007/s10549-020-05615-4
________________________________________________
2. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7 (9): 987–9.
3. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58–62.
4. Duda DG, Jain RK, Willett CG. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25 (26): 4033–42.
5. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27 (30): 4966–72.
6. Miles DW, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26 (43s).
7. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29 (10): 1252–60.
8. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010; 28 (Suppl. 15): 1005.
9. Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients Ann Oncol [epub ahead of print on September 5, 2010].
10. Smith I, Pierga JY, Biganzoli L, et al. Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 2011; 130: 133.
11. Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer. Lancet Oncol 2014; 15 (12): 1351–60.
12. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. J Clin Oncol 2011; 29 (32): 4286–93. DOI: 10.1200/jco.2010.34.1255
13. O’Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: Phase III Trials of Bevacizumab with Standard Chemotherapy for Metastatic Breast Cancer. Clin Breast Cancer 2008. 8(4); 370–3. DOI: 10.3816/cbc.2008.n.045
14. Nahleh Z, Botrus G, Dwivedi A, et al. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol 2019; 10: 357–65.
15. Hardy-Bessard AC, Brocard F, Clatot F, et al. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast 2020; 54: 256–63. DOI: 10.1016/j.breast.2020.09.011
16. De Angelis C, Bruzzese D, Bernardo A, et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open 2021; 6 (2): 100054. DOI: 10.1016/j.esmoop.2021.100054. PMID: 33601296.
17. Hirai T, Nemoto A, Ito Y, et al. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer. Breast Cancer Res Treat 2020; 181: 189–98. DOI: 10.1007/s10549-020-05615-4
Авторы
И.П. Ганьшина*1, К.А. Иванова1, О.О. Гордеева1, А.В. Архипов2, Л.Г. Жукова3
1 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия;
2 ФГАУ «Национальный медицинский исследовательский центр ”Лечебно-реабилитационный центр”» Минздрава России, Москва, Россия;
3 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия
*ganshinainna77@mail.ru
1 Blokhin National Medical Research Center of Oncology, Moscow, Russia;
2 National Medical Research Center "Treatment and Rehabilitation Center", Moscow, Russia;
3 Loginov Moscow Clinical Scientific and Practical Center, Moscow, Russia
*ganshinainna77@mail.ru
1 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия;
2 ФГАУ «Национальный медицинский исследовательский центр ”Лечебно-реабилитационный центр”» Минздрава России, Москва, Россия;
3 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия
*ganshinainna77@mail.ru
________________________________________________
1 Blokhin National Medical Research Center of Oncology, Moscow, Russia;
2 National Medical Research Center "Treatment and Rehabilitation Center", Moscow, Russia;
3 Loginov Moscow Clinical Scientific and Practical Center, Moscow, Russia
*ganshinainna77@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.